Iconiq Lab, a global initial coin offering (ICO) and token sale accelerator program based in Germany, will soon launch two new branches in the US and Asia, Patrick Lowry, CEO of Iconiq Lab, told ...
iCo’s main focus is on advancing its lead program, iCo-007, into phase 2 trials for the treatment of a Diabetes-related eye disease. Immune Pharma is paying iCo an option fee that will be credited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback